Bristol Myers Squibb highlights latest cardiovascular portfolio data at ESC Congress 2025

Bristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain. Data to be presented at the meeting include new real-world analyses of Camzyos (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) as well as data on behalf of the BMS-Pfizer Alliance on Eliquis (apixaban).

“With a 70-year legacy in cardiovascular medicine, we are deeply committed to advancing life-changing therapies for patients, including those living with symptomatic obstructive HCM,” said Roland Chen MD, senior vice president, drug development, Immunology and Cardiovascular Medicines, Bristol Myers Squibb. “Camzyos is the first and only available cardiac myosin inhibitor supported by robust long-term extension and real-world effectiveness data in patients with oHCM, with clinical studies demonstrating symptom relief as well as improvements in functional capacity and cardiac structure, both with and without background therapy. We look forward to sharing new data at this year’s ESC Congress building on our growing body of real-world evidence that reinforce its overall safety profile and benefits for diverse patients around the world.”

Key presentations include:

• An oral presentation showing real-world outcomes for Camzyos for the treatment of symptomatic oHCM from COLLIGO-HCM, a global observational study reflecting diverse patient populations in five countries (the United States, Canada, the United Kingdom, Australia, and Israel).
• An oral presentation spotlighting the efficacy and safety of Camzyos monotherapy in treating patients with oHCM based on a pooled analysis of four Phase 3 studies.
• A late-breaking oral presentation highlighting topline results from ODYSSEY-HCM, a Phase 3 randomized, double-blind, placebo-controlled trial in 580 adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM), the largest and longest-duration study completed to date in this patient population.

Select abstracts sponsored by Bristol Myers Squibb and the BMS-Pfizer Alliance to be presented at ESC Congress 2025 can be found below. Complete abstracts may be accessed online here. Visit the following page on BMS.com for more information on Bristol Myers Squibb’s scientific approach to and resources on cardiovascular diseases.

View select abstracts sponsored by Bristol Myers Squibb and the BMS-Pfizer Alliance to be presented at ESC Congress 2025 HERE.